title: IL-6 Differs from TNF-α: Unpredicted Clinical Effects Caused by IL-6 Blockade in Psoriasis.
abstract: IL-6 is a pleiotropic proinflammatory cytokine that is elevated in serum and skin lesions of patients with psoriasis. Anti-IL-6 therapies, however, which are effective for rheumatoid arthritis, are either ineffective for psoriasis or can induce new-onset psoriasis-like disease. Fritz et al. provide a potential explanation for these clinical observations by examining IL-17C-driven psoriasis-like disease in mice with an IL-6-deficient genetic background. These mice displayed slower onset skin disease initially, but then worsened over time, suggesting that a lack of IL-6 led to compensatory proinflammatory effects by other cytokines, which eventually worsened the psoriatic inflammation.
authors.affiliation: Oregon Medical Research Center, Portland, Oregon, USA. Electronic address: ablauvelt@oregonmedicalresearch.com.
authors.forename: Andrew
authors.initials: A
authors.lastname: Blauvelt
mesh_terms: D000818:Animals; D006801:Humans; D020381:Interleukin-17 / Q000235:genetics; D015850:Interleukin-6 / Q000235:genetics*; D051379:Mice; D011565:Psoriasis; D012867:Skin; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics*
chemical_list: D020381:Interleukin-17; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha